CJC-1295 for Recovery

What Is CJC-1295 and Why Is It Used Off-Label?

CJC-1295 is a synthetic 30-amino-acid peptide analog of endogenous GHRH, modified at four positions (Ala2, Asn8, Ala15, Leu27) to resist dipeptidyl peptidase IV (DPP-IV) cleavage [1]. Two forms circulate in clinical and compounding contexts: the Drug Affinity Complex (DAC) version, which covalently binds albumin to extend its half-life to roughly 5.8 to 8 days, and the non-DAC version (often called modified GRF 1-29 or mod-GRF), with a half-life near 30 minutes [2].

Neither form has received FDA approval. The FDA's approved GHRH analogs are limited to tesamorelin (Egrifta), indicated only for HIV-associated lipodystrophy [3]. CJC-1295 occupies a regulatory gray zone: it is available through 503A and 503B compounding pharmacies, and the FDA has issued warning letters to firms marketing it for anti-aging or performance claims [4]. Recovery-focused use (post-exercise soreness reduction, tendon or ligament healing acceleration, post-surgical tissue repair) is entirely off-label. Clinicians who prescribe it draw on the well-characterized anabolic and reparative effects of the GH-IGF-1 axis rather than on direct evidence for CJC-1295 itself [5].

Pharmacology: How CJC-1295 Raises GH and IGF-1

The peptide binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, triggering cyclic AMP signaling and dose-dependent GH secretion [6]. In the key Phase I/II ascending-dose study by Teichman et al. (2006, N=56 healthy adults), a single 30 mcg/kg subcutaneous dose of CJC-1295 DAC increased mean GH levels 2- to 10-fold above baseline, with elevation persisting for at least 6 days [2]. Mean IGF-1 rose 1.5- to 3-fold and remained above baseline at day 11 [2].

This prolonged pharmacodynamic profile distinguishes CJC-1295 DAC from native GHRH, which produces a GH pulse lasting under 2 hours [7]. The non-DAC form (mod-GRF 1-29) generates a shorter but sharper GH pulse, and practitioners often pair it with a ghrelin mimetic such as ipamorelin to amplify pulsatile release [8]. GH in turn stimulates hepatic and local IGF-1 production, the downstream effector most directly tied to collagen synthesis, satellite cell activation, and protein accretion in skeletal muscle [9].

The GH-IGF-1 Axis in Recovery: What the Evidence Actually Shows

GH and IGF-1 are established regulators of tissue repair. That statement rests on decades of mechanistic and clinical data, not on CJC-1295 trials per se. Recombinant human GH (rhGH) accelerated nitrogen balance recovery in burn patients (Herndon et al., Annals of Surgery, 1990) [10] and improved wound healing velocity in a randomized trial of elderly hip-fracture patients (N=20, Yeo et al., 2003) [11]. IGF-1 infusion increased muscle protein synthesis rates by 47% in healthy volunteers (Fryburg et al., 1995), confirming the anabolic signal that recovery-focused CJC-1295 prescribers hope to replicate [12].

For connective tissue, systemic GH administration for 14 days increased collagen type I and III mRNA expression in human tendon biopsies (Doessing et al., 2010, N=20) [13]. A 2005 systematic review in the Journal of Bone and Joint Surgery found moderate evidence that GH supplementation improved fracture healing rates in animal models, though human fracture data remained sparse [14].

The inferential chain is: CJC-1295 raises endogenous GH and IGF-1, and elevated GH/IGF-1 promotes tissue repair. That logic is pharmacologically plausible. It is not the same as proven. No published randomized controlled trial has administered CJC-1295 to injured or post-surgical subjects and measured a recovery endpoint such as return-to-play time, wound tensile strength, or muscle damage biomarker clearance.

Clinical Trial Data Specific to CJC-1295

Published human data on CJC-1295 are narrow. The Teichman et al. Phase I/II dose-escalation study (2006) established PK/PD parameters and short-term safety in 56 healthy men and women [2]. A follow-on multiple-dose study confirmed sustained GH and IGF-1 elevation with weekly injections over 12 weeks, but the primary endpoint was hormonal, not functional [15].

An unpublished Phase II trial of CJC-1295 DAC for GH-deficient adults was terminated early after one subject death. The cause was not fully disclosed publicly, but the trial's discontinuation limited further clinical development of the DAC formulation [16]. This event is not a contraindication to the non-DAC mod-GRF peptide (a distinct pharmacokinetic profile with shorter exposure), but it underscores that safety data remain incomplete.

No registered trials on ClinicalTrials.gov currently list CJC-1295 with recovery, rehabilitation, or tissue-healing endpoints [17]. The Endocrine Society's 2019 clinical practice guideline on GH use in adults does not mention CJC-1295 or any GHRH analog for recovery indications; it restricts GH replacement to patients with confirmed GH deficiency diagnosed by validated stimulation testing [18].

How Practitioners Use CJC-1295 Off-Label for Recovery

Despite the evidence gap, compounding pharmacy data and clinician surveys indicate growing off-label use. Typical protocols reported in anti-aging medicine literature include mod-GRF 1-29 at 100 mcg subcutaneously, often combined with ipamorelin 100 to 200 mcg, administered 1 to 3 times daily, 5 days on and 2 days off [8]. Timing is usually pre-sleep to coincide with endogenous nocturnal GH pulsatility [19].

Clinicians targeting post-exercise recovery often run 8- to 12-week cycles, monitoring IGF-1 serum levels every 4 weeks. Target IGF-1 ranges vary by practice, but most aim for the upper quartile of the age-adjusted reference range (roughly 200 to 300 ng/mL for adults aged 30 to 50) without exceeding it [18]. CJC-1295 DAC, dosed at 1 to 2 mg subcutaneously once weekly, produces a more sustained IGF-1 elevation and is sometimes preferred for patients who want fewer injections [2].

These protocols are experience-based. No dose-finding study has optimized CJC-1295 for any recovery metric. The Anti-Aging and Regenerative Medicine fellowship community has published consensus opinions but not randomized data [20].

Comparing CJC-1295 to FDA-Approved Alternatives

Tesamorelin (Egrifta) is the only FDA-approved GHRH analog. Its labeled indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [3]. Tesamorelin raises GH comparably to CJC-1295 (mean 24-hour GH AUC increased approximately 2-fold), and its Phase III trials (N=816) documented concurrent IGF-1 elevation [21]. However, its approval pathway focused on visceral adiposity, not on musculoskeletal recovery.

Recombinant GH (somatropin) itself is FDA-approved for adult GH deficiency, Turner syndrome, chronic renal insufficiency, and several other conditions [22]. Off-label rhGH for sports recovery is banned by WADA and carries supraphysiologic exposure risks including carpal tunnel syndrome, edema, and insulin resistance [23]. CJC-1295's theoretical advantage is a more physiologic pulsatile GH release pattern, since it stimulates the pituitary rather than replacing GH directly. Whether this translates into a better safety or efficacy profile remains unproven.

Sermorelin, another GHRH analog (GRF 1-29 without amino acid substitutions), was previously FDA-approved for diagnostic use and pediatric GH deficiency but was withdrawn from the market for commercial reasons, not safety [24]. It shares CJC-1295's mechanism but has a shorter half-life (10 to 20 minutes) and weaker receptor binding affinity.

Safety Profile and Risks

Short-term adverse events in the Teichman et al. trial included injection-site erythema (10 to 25% of subjects), transient flushing, diarrhea, and headache [2]. Dose-proportional injection-site induration was the most common local reaction with the DAC formulation.

The single death in the unpublished CJC-1295 DAC trial introduces uncertainty that cannot be dismissed. Without a published autopsy or causality analysis, the event remains unexplained [16]. Practitioners using the non-DAC peptide (mod-GRF 1-29) argue that its brief half-life limits cumulative GH exposure and reduces risk, but this is a theoretical distinction without comparative safety data.

Chronic GH elevation, regardless of the stimulus, carries metabolic consequences. The Endocrine Society warns that supraphysiologic IGF-1 levels are associated with increased colorectal and prostate cancer risk in epidemiologic studies, though a causal relationship is not established [18]. Patients using CJC-1295 long-term (beyond 12 weeks) should have IGF-1, fasting glucose, and hemoglobin A1c monitored at minimum [18]. Joint stiffness, water retention, and new-onset carpal tunnel symptoms should prompt dose reduction or discontinuation.

CJC-1295 is not classified as a controlled substance under federal law, but it falls outside FDA-approved drug categories. WADA prohibits all GH-releasing peptides in competition and out-of-competition testing [23]. Athletes subject to anti-doping rules cannot use it.

Evidence Grade Summary

By GRADE framework criteria, the evidence for CJC-1295 as a recovery agent rates as very low. The body of evidence consists of indirect pharmacodynamic studies (healthy-volunteer PK/PD data showing GH and IGF-1 elevation), extrapolation from rhGH trials in different populations (burns, hip fractures, GH-deficient adults), and absence of any directly relevant RCT [25]. Imprecision is high because no study has measured a recovery-specific outcome after CJC-1295 administration. Risk of bias is unassessable for the unpublished terminated trial.

The Endocrine Society, AACE, and FDA have not issued statements endorsing or specifically prohibiting CJC-1295 for recovery [18]. It remains a pharmacologically rational but clinically unvalidated intervention.

Who Might Be a Candidate (and Who Is Not)

Practitioners offering CJC-1295 for recovery typically screen for confirmed low or low-normal IGF-1 (below the 25th percentile for age), subjective delayed recovery from training or injury, and absence of contraindications including active malignancy, uncontrolled diabetes, or proliferative retinopathy [18]. Patients with a history of pituitary adenoma or elevated baseline IGF-1 should not receive GHRH analogs [18].

Women who are pregnant or breastfeeding lack any safety data for CJC-1295. Adolescents with open growth plates face theoretical risk of accelerated epiphyseal closure, though this has not been studied with CJC-1295 specifically [22].

The American College of Sports Medicine's position stand on GH and sport does not address GHRH analogs individually but states that evidence does not support GH use for enhancing athletic performance in healthy adults [26].